secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001213900-25-052295
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics updates pipeline timelines, reports cash runway and share count in corporate deck
--------------------------------------------------------------------------------

- Cash on hand sufficient to fund all clinical and preclinical programs in development.
- 13.2 million shares outstanding as of June 6, 2025; no outstanding debt noted.
- HT-001 Phase 2a open-label PK data expected Q1 2025; full dataset Q4 2025.
- HT-KIT IND submission targeted Q1 2026; GLP tox & GMP API manufacturing initiated Q1 2025.
- HT-ALZ pre-IND meeting submission planned for 2025; 505(b)(2) pathway pursued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025052295/0001213900-25-052295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390025052295/ea0245073-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-052295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer